FDBusiness.com

Swiss biopharmaceutical company Evolva Holding and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.

This additional collaboration between the two companies is modelled on the first partnership signed in March 2013 to develop next-generation stevia ingredients (steviol glycosides). This second family of high-value ingredients is unrelated to stevia. In the initial phase of the new collaboration, Evolva expects to deploy 5 -7 researchers. Evolva and Cargill will share costs.

Neil Goldsmith, CEO of Evolva, comments: “Obviously, signing a second product collaboration agreement with Cargill—just under two years after starting our stevia collaboration with them—speaks to the confidence that both companies have about the fermentation route of production for a wide variety of functional ingredients. We are pleased that our relationship with Cargill continues to deepen.”

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make.